TY - JOUR
T1 - A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis
T2 - Ineffectiveness in head-and-neck dermatitis
AU - Vittrup, Ida
AU - Krogh, Niels Steen
AU - Larsen, Henrik Hedegaard Pliess
AU - Elberling, Jesper
AU - Skov, Lone
AU - Ibler, Kristina Sophie
AU - Jemec, Gregor B E
AU - Mortz, Charlotte G
AU - Bach, Rasmus Overgaard
AU - Bindslev-Jensen, Carsten
AU - Dalager, Maiken Glud
AU - Egeberg, Alexander
AU - Agner, Tove
AU - Deleuran, Mette
AU - Vestergaard, Christian
AU - Thyssen, Jacob Pontoppidan
N1 - © 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2023/5
Y1 - 2023/5
N2 - BACKGROUND: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.OBJECTIVES: To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.METHODS: We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017-2022.RESULTS: At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6-25.2), at week 4: 6.5 (3.5-11.6), at week 16: 3.7 (1.2-6.2), at week 52: 2.0 (0.8-3.6), at week 104: 1.7 (0.8-3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.CONCLUSIONS: While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
AB - BACKGROUND: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.OBJECTIVES: To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.METHODS: We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017-2022.RESULTS: At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6-25.2), at week 4: 6.5 (3.5-11.6), at week 16: 3.7 (1.2-6.2), at week 52: 2.0 (0.8-3.6), at week 104: 1.7 (0.8-3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.CONCLUSIONS: While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
KW - Adult
KW - Conjunctivitis/drug therapy
KW - Dermatitis, Atopic/drug therapy
KW - Double-Blind Method
KW - Humans
KW - Injections, Subcutaneous
KW - Severity of Illness Index
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85147025383&partnerID=8YFLogxK
U2 - 10.1111/jdv.18849
DO - 10.1111/jdv.18849
M3 - Journal article
C2 - 36606551
SN - 0926-9959
VL - 37
SP - 1046
EP - 1055
JO - Journal of the European Academy of Dermatology and Venereology : JEADV
JF - Journal of the European Academy of Dermatology and Venereology : JEADV
IS - 5
ER -